AI Summary & Key Takeaways
AI InsightImprovement of liver necroinflammation was detected, but no significant change observed in fibrosis.
📌 3 Key Takeaways
Abstract
Objective: The aim of this study to evaluate histopathological improvement and virological, serological and biochemical response rates inpatients with chronic hepatitis B (CHB) who were treated with tenofovir disoproxil fumarate (TDF).Material and Method: A total of 91 nucleosid(t)e-naive CHB patients who received TDF were evaluated. Virological, serological and biochemicaltest results were assessed at baseline and every 12 weeks. Liver biopsy specimens were assessed according to the modified Ishak scoring.Results: The study was conducted on 52 patients. The mean age was 40±10 years and 40.4% were female. The mean follow-up period was 33±11months. HBsAg seroclearance occurred in none of the patients. The serum level of HBV-DNA became undetectable in 94.2% of the patients.Mean histological activity index at baseline and on-treatment were 8.2±2.3 and 6.2±2.0 and the mean fibrosis scores were 2.65±1.3 and 2.33±1.1,respectively.Conclusion: We determined that TDF therapy provided remarkably good HBV DNA suppression and biochemical response rates, but lowseroconversion. Improvement of liver necroinflammation was detected, but no significant change observed in fibrosis.